Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-21 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy in women who elect to use an oral contraceptive
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
400 mg orally once daily with food.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin.
98% bound to albumin
Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction),Hepatic disease (e.g., jaundice, liver tumors),Hypertension,Carbohydrate and lipid metabolism effects,Headache/migraine,Bleeding irregularities,Depression,Gallbladder disease,Hereditary angioedema,Pregnancy and postpartum use,Ophthalmic complaints (contact lens intolerance, retinal thrombosis)
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
High risk of arterial or venous thrombotic diseases (e.g., known thrombophilia, history of DVT/PE, cerebrovascular disease, coronary artery disease),Current or history of breast cancer or other estrogen-sensitive cancer,Hepatic adenoma or carcinoma, or active liver disease,Undiagnosed abnormal uterine bleeding,Pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Hypertension uncontrolled or with vascular disease,Migraine with aura if >35 years,Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may increase estrogen exposure; avoid large amounts. Taking with food can reduce nausea.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Combined hormonal contraceptives may reduce milk production and quality, especially in early postpartum. Small amounts of estrogen and progestin are excreted in breast milk; the M/P ratio is not well defined for this specific formulation. Use is generally not recommended during breastfeeding, particularly before weaning or beyond 6 weeks postpartum when milk supply is established. Alternatives (progestin-only) are preferred.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable; this drug is contraindicated during pregnancy. No dose adjustments are made for pregnancy as it is not used in that setting. Pharmacokinetic changes of pregnancy (e.g., increased clearance) are not relevant because use is avoided.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
This triphasic oral contraceptive contains norethindrone and ethinyl estradiol. The 7/7/7-21 regimen uses three different hormone doses over 21 days followed by 7 placebo pills. Monitor for breakthrough bleeding, especially during dose transitions. Assess for contraindications including history of DVT, PE, migraine with aura, breast cancer, liver disease, or age >35 with smoking. Consider CYP3A4 interactions; rifampin, certain anticonvulsants, and St. John's wort may reduce efficacy.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Start pack on first day of period or first Sunday after; use backup contraception for first 7 days if starting later.,Common side effects: nausea, breast tenderness, breakthrough bleeding; usually improve within 3 cycles.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects.,Seek emergency care if signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,Some medications (antibiotics, seizure meds, St. John's wort) may decrease effectiveness; inform all healthcare providers.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-21 vs ADQUEY, answered by our medical review team.
ORTHO-NOVUM 7/7/7-21 is a Oral Contraceptive that works by Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-21 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-21 is: One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-21 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-21 is classified as Category C. Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current da. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.